1-溴-3-叔丁基苯 | 3972-64-3

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-3-叔丁基苯
• 中文别名: 3-叔丁基溴苯；3-溴叔丁基苯
• 英文名称: 1-bromo-3-(tertbutyl)benzene
• 英文别名: 3-tert-butylbromobenzene；3-Brom-t-butyl-benzol；3-Brom-tert-butylbenzol；1-bromo-3-(t-butyl)benzene；m-bromo-tert-butylbenzene；1-Brom-3-tert-butyl-benzol；3-bromo-tert-butyl benzene；3-Brom-1-t-butyl-benzol；3-t-butylbromobenzene；m-Brom-t-butylbenzol；1-Bromo-3-tert-butylbenzene
• CAS: 3972-64-3
• 化学式: C₁₀H₁₃Br
• 分子量: 213.117
• InChiKey: FDXXHPYFJDKWJS-UHFFFAOYSA-N

物化性质

• 熔点：
  23.51° C (Predicted)
• 沸点：
  95-97°C
• 密度：
  1.251 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险品标志：
  C
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温下应存放在干燥密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-3-tert-butylbenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-3-tert-butylbenzene
CAS number: 3972-64-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13Br
Molecular weight: 213.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

1-溴-3-叔丁基苯在常温常压下为无色透明液体状。由于溴原子具有高化学反应活性，该物质可参与多种过渡金属催化的偶联反应。此外，它还能与镁粉发生反应，用于制备相应的格式试剂。

应用

1-溴-3-叔丁基苯含有一个溴原子和一个大位阻的叔丁基。借助叔丁基的大位阻特性，该物质在手性配体结构修饰及合成中具有一定的应用价值。苯环上的溴原子具有较好的反应活性，可用来制备相应的格式试剂，并在过渡金属催化作用下发生各种偶联反应。在过渡金属催化的偶联反应中，1-溴-3-叔丁基苯可以作为芳基卤化物的底物，与其他亲核性化合物进行偶联反应，从而形成新的芳香族化合物。

反应信息

• 作为反应物：
  描述：

  1-溴-3-叔丁基苯 在 palladium 10% on activated carbon 、 氢气 、 magnesium 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 65.0 ℃ 、101.33 kPa 条件下， 反应 48.0h， 生成 1-异丙基-3-(2-甲基-2-丙基)苯
  参考文献：
  名称：

  C（sp3）–C（sp3）σ键的简便氢解

  摘要：

  通过钯催化的C（sp 3）–C（sp 3）氢解对苄基的季碳，叔碳和仲碳中心进行修饰）呈现σ键。当在温和的氢解条件下（含钯碳和氢气的大气压）处理带有季苄基中心的苄基麦德鲁姆的酸衍生物时，就可以很好地获得高收率的芳族化合物，这些芳族化合物被叔苄基中心和麦德鲁姆酸所取代。类似地，含有叔或仲苄基中心的底物分别产生被仲苄基中心或甲苯衍生物取代的芳族化合物。此外，该策略用于二芳基甲烷的高产率合成。探索了还原性脱烷基反应的范围，并确定了对空间和电子因素的限制。描述了该反应的机理分析，该分析由氘标记实验和对映体富集的衍生物的氢解组成。调查显示，C（sp 3）–C（sp 3）σ键断裂事件是通过混合的S N 1 / S N 2机理发生的，其中钯中心置换了一个基于碳的离去基团，即Meldrum酸，其构型反转，随后通过还原消除钯来提供CH键。

  DOI：

  10.1002/adsc.201600535
• 作为产物：
  描述：

  3-叔丁基苯酚 在 triphenylphosphine dibromide 1:1 addition complex 作用下， 以30%的产率得到1-溴-3-叔丁基苯
  参考文献：
  名称：

  Cyclodextrin-mediated chiral sulfoxidations

  摘要：

  DOI：

  10.1021/jo00179a033
• 作为试剂：
  描述：

  1-tert-butyl-3-ethynyl-benzene 、 间溴苯甲酸 、 三甲基铝 在 1-溴-3-叔丁基苯 作用下， 以 正己烷 为溶剂， 以to yield 3-tert-butyl bromobenzene (Compound 26)的产率得到1-溴-3-叔丁基苯
  参考文献：
  名称：

  Acetylenes disubstituted with a heteroaromatic group and a substituted

  摘要：

  化合物的公式为##STR1##，其中R.sub.1-R.sub.3独立地为氢、低碳烷基、环烷基或低烯基，A和B独立地为氢、低碳烷基、环烷基、低烯基、SR.sub.4或OR.sub.4，其中R.sub.4为低碳烷基、环烷基或低烯基；Y选自吡嗪基、嘧啶基、吡嗪基或噁唑基的群；E为低烯基、低炔基、低环烷基、低支链烷基，或由式(CH.sub.2).sub.n表示，其中n为0-5，而Z为H、OH、OR.sub.5、OCOR.sub.5、--COOH或其药学上可接受的盐、酯或酰胺、--CH.sub.2 OH、CH.sub.2 OR.sub.6、CH.sub.2 OCOR.sub.6或--CHO、CH(OR.sub.7).sub.2、CHOR.sub.8 O或COR.sub.9、CR.sub.9 (OR.sub.7).sub.2、CR.sub.9 OR.sub.8 O，其中R.sub.5为低碳烷基、苯基或低碳烷基苯基，R.sub.6为低碳烷基、苯基或低碳烷基苯基，R.sub.7为低碳烷基，R.sub.8为2-5碳的二价烷基基团，R.sub.9为含有1-5碳的烷基、环烷基或烯基基团。

  公开号：

  US05516904A1

文献信息

• [EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS<br/>[FR] PROCEDES DE TRAITEMENT D'AMYLOIDOSE UTILISANT DES INHIBITEURS DE PROTEASE ASPARTYLE
  申请人：ELAN PHARM INC

  公开号：WO2005070407A1

  公开（公告）日：2005-08-04

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的疾病、疾病和症状。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、疾病和症状。
• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2017214505A1

  公开（公告）日：2017-12-14

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物、以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。
• INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
  申请人：Praxis Biotech LLC

  公开号：US20190185451A1

  公开（公告）日：2019-06-20

  Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

  描述了用于调节成纤维细胞活化蛋白（FAP）的化合物和组合物。这些化合物和组合物可能被用作治疗疾病的治疗剂，包括高增殖性疾病。
• Pd‐Catalyzed Synthesis of Vinyl Arenes from Aryl Halides and Acrylic Acid
  作者：Yang Gao、Yang Ou、Lukas J. Gooßen

  DOI：10.1002/chem.201902022

  日期：——

  reaction of acrylic acid, immediately followed by protodecarboxylation of the cinnamic acid intermediate. The use of the carboxylate group as a deciduous directing group ensures high selectivity for monoarylated products. The vinylation process is generally applicable to diversely substituted substrates. Its utility is shown by the synthesis of drug‐like molecules and the gram‐scale preparation of key intermediates

  在钯催化的芳基卤化物的脱羧乙烯基化中，丙烯酸是一种廉价，不挥发的乙烯基化剂。该反应通过丙烯酸的Heck反应进行，然后立即进行肉桂酸中间体的原脱羧。羧酸根基团作为落叶指导基团的使用确保了对单芳基化产物的高选择性。乙烯基化方法通常适用于各种取代的底物。药物样分子的合成和药物合成关键中间体的克级制备证明了其实用性。